Your browser doesn't support javascript.
loading
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C; Hart, Lowell L; Jones, Robert; McDermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; MacLean, David B; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I; Dreicer, Robert; Webb, Iain J; de Wit, Ronald.
Afiliação
  • Saad F; Centre Hospitalier de l'Université de Montréal/CRCHUM, Montréal, QC, Canada. Electronic address: fred.saad@umontreal.ca.
  • Fizazi K; Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
  • Jinga V; Universitatea de Medicina si Farmacie, Bucharest, Romania.
  • Efstathiou E; University of Athens Medical School, Athens, Greece.
  • Fong PC; Auckland City Hospital, Auckland, New Zealand.
  • Hart LL; Florida Cancer Specialists, Fort Myers, FL, USA.
  • Jones R; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • McDermott R; The Adelaide and Meath Hospital, Incorporating the National Children's Hospital, Dublin, Ireland.
  • Wirth M; University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
  • Suzuki K; Gunma University Graduate School of Medicine, Gunma, Japan.
  • MacLean DB; Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Wang L; Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Akaza H; The University of Tokyo Research Center for Advanced Science and Technology, Tokyo, Japan.
  • Nelson J; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Scher HI; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Dreicer R; Cleveland Clinic, Cleveland, OH, USA.
  • Webb IJ; Millennium Pharmaceuticals, Inc, Cambridge, MA, USA.
  • de Wit R; Erasmus University Medical Center, Rotterdam, Netherlands.
Lancet Oncol ; 16(3): 338-48, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25701170
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male País/Região como assunto: America do norte / Asia / Europa / Oceania Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male País/Região como assunto: America do norte / Asia / Europa / Oceania Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article